Document is current
Any future updates will be listed below
-
Authors
Yoshida, Atsushi https://orcid.org/0009-0009-9333-6729
Takagi, Tomohisa
Kawashima, Kousaku
Moriya, Kei
Bamba, Shigeki
Sagami, Shintaro
Hayashi, Tomoyuki
Kaneko, Motoki
Naito, Takeo
Kanmura, Shuji
Asaeda, Kohei
Ishihara, Shunji
Nagamatsu, Shinsaku
Endo, Yutaka
Ueno, Fumiaki
Morizane, Toshio
Matsuoka, Katsuyoshi
Hibi, Toshifumi
- License Information
-
More Information
Article History
Received: 20 June 2025
Accepted: 26 October 2025
First Online: 7 November 2025
Declarations
:
: A. Yoshida received personal fees from Mitsubishi-Tanabe Pharma, Janssen Pharmaceutical K.K., Abbvie Inc., EA Pharma Co., Ltd., Nippon Kayaku Co. Ltd., Takeda Pharmaceutical Co. Ltd., Pfizer Inc, Mochida Pharmaceutical Co., Ltd. T. Takagi received research funding from Mitsubishi-Tanabe Pharma, and Pre. Media, Inc., and lecture fees from Mitsubishi-Tanabe Pharma, Janssen Pharmaceutical K.K., Abbvie Inc., EA Pharma Co., Ltd., Towa Co. Ltd., Takeda Pharmaceutical Co. Ltd., Pfizer Inc, Mochida Pharmaceutical Co., Ltd.. S. Sagami received personal fees from Mitsubishi-Tanabe Pharma, Janssen Pharmaceutical K.K., Abbvie Inc., Takeda Pharmaceutical Co., Ltd. S. Ishihara received personal fees from Takeda Pharmaceutical Co. Ltd., Abbvie Inc.. K. Matsuoka has received personal fees from Mitsubishi-Tanabe Pharma, Takeda Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., AbbVie Inc., EA Pharma Co., Ltd, Pfizer Inc., Mochida Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Zeria Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., and Gilead Sciences; research grants from Mitsubishi-Tanabe Pharma, AbbVie Inc., EA Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Zeria Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., and has a leadership advisory role for EA Pharma Co., Ltd., Eli Lilly, Bristol-Myers Squibb, and Janssen Pharmaceutical K.K.. T. Hibi has received lecture fees from, Abbvie, EA Pharma, Janssen, JIMRO, Mitsubishi-Tanabe Pharma, Mochida Pharmaceutical, Pfizer, Sandoz. Takeda Pharmaceutical, Zeria; advisory/consultancy fees from Abbvie GK, Celltrion Healthcare Japan K.K., EA Pharma Lilly, Gilead Sciences, Janssen, Mitsubishi-Tanabe Pharma, Nichi-Iko Pharmaceutical, Nippon Kayaku, Takeda, Zeria and research grants from Abbvie, Activaid, Alfresa Pharma Corporation, Bristol-Myers Squibb., Eli Lilly, Ferring, Gilead Sciences, JIMRO JMDC Inc., Janssen Pharmaceutical, Kyorin, Miyarisan., Mochida Pharmaceutical, Nippon Kayaku, Pfizer, Zeria Pharmaceutical Co, Ltd.. Other authors have declared no conflicts of interest.
: We conducted this study in compliance with the latest version (2013) of the Declaration of Helsinki. The study was approved by the ethics committee of Ofuna Chuo Hospital (No. 2020–015, No. 2022-001, No. 2022-010). All enrolled patients provided informed consent.
